Agile therapeutic partners with –


PRINCETON, NJ, September 28, 2021 (GLOBE NEWSWIRE) – Agile Therapeutics, Inc. ( AGRX), a women’s healthcare company, today announced a partnership with American women’s football legend, Carli Lloyd. The partnership with Agile will focus on raising awareness of topics related to women’s health and Agile’s commitment to improving women’s health care.

Lloyd, who will play it final match for the United States Women’s National Team on October 26e against South Korea, was drawn to the company’s mission to meet the health needs of today’s women.

“I am delighted to be partnering with a company entirely dedicated to women’s health,” said Lloyd. “I intend to work with organizations that focus on things that are close to my heart, and staying healthy has been a priority for my career in the field and will continue to be as I prepare. to my next chapter. Agile’s focus on providing women with options and knowledge when it comes to their healthcare decisions is a mission I’m proud to be a part of. And the fact that I’m a girl from New Jersey, representing a New Jersey company, makes it even better.

Agile has built its brand around a commitment to meet women’s health needs. It received US Food and Drug Administration (FDA) approval in February 2020 for its first product, Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, a weekly contraceptive patch. He currently has four additional contraceptive products in its pipeline.

“Carli’s’always believe and never give up‘attitude is what Agile Therapeutics believes as a company, ”said Al Altomari, CEO of Agile Therapeutics. “We have chosen to align with the right partners at the right time, and Carli is a person who fits perfectly into our corporate culture, aligns with our values ​​and understands the importance of giving to women, in particular to young women, the means to go beyond their limits. , believe in themselves and never compromise, especially with their health care.

As a growing company, Agile sees this partnership as an opportunity to help further develop its corporate culture and brand by partnering with leaders who share the values ​​and mission of the company.

“Our short term goal is to establish Twirla in the contraceptive market, and our long term mission remains the same: to build a strong franchise for women’s health, and Carli is a vital piece of that puzzle,” said Altomari. “She has been a strong advocate for women, and her voice is important in the national conversation about women’s health and health care needs. We want to make sure that we communicate our message and our commitment to women’s health in an authentic and relevant way. It is a mission that we share with Carli, and we are proud to welcome him to our team.

About Agile Therapeutics, Inc.
Agile Therapeutics is a women’s healthcare company dedicated to meeting the unmet health needs of women today. Our product and product candidates are designed to provide women with birth control options that provide the freedom to take a daily pill, without committing to a longer method of action. Our original product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company’s website at The Company may occasionally post material, non-public information on the Company’s website.

About Twirla®
The Twirla transdermal system (levonorgestrel and ethinyl estradiol) is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Twirla is indicated as a method of contraception in women of childbearing potential with a body mass index (BMI) 2 for whom a combined hormonal contraceptive is appropriate. Healthcare providers (HCPs) are encouraged to consider reduced effectiveness of Twirla in women with a BMI ≥ 25 to 2 before prescribing. Twirla is contraindicated in women with a BMI ≥ 30 kg / m2. Twirla is contraindicated in women over 35 who smoke. Smoking increases the risk of serious cardiovascular events related to the use of CHCs. Twirla is designed to be applied once a week for three weeks, followed by a week without a patch.

Media inquiries:
Matt riley
Head of Investor Relations and Corporate Communication
[email protected]



Comments are closed.